Clinical patterns and significance of non-compliance with guideline-recommended treatment of acute pulmonary embolism.


Journal

Archives of cardiovascular diseases
ISSN: 1875-2128
Titre abrégé: Arch Cardiovasc Dis
Pays: Netherlands
ID NLM: 101465655

Informations de publication

Date de publication:
Jan 2020
Historique:
received: 10 05 2019
revised: 09 09 2019
accepted: 30 09 2019
pubmed: 7 11 2019
medline: 23 6 2020
entrez: 7 11 2019
Statut: ppublish

Résumé

Evidence-based clinical practice guidelines define initial management of acute pulmonary embolism (PE) according to risk stratification for early death. The aims of the present study were to investigate patterns of non-compliance with guidelines for the acute PE treatment, and the associated risk of adverse events. We performed an observational, multicentre, cohort study of acute PE. Inclusion criteria were all patients with pulmonary embolism admitted to the participating centres between January 2011 and April 2017. The measure of 100% compliance was used to allocate patients in the compliant or non-compliant groups. The primary outcome was all-cause death at 6 months. Secondary outcomes included recurrent venous thromboembolism and major bleeding. In total, 1285 patients were included. Treatment was not in compliance with the guidelines in 172 patients (13.4%). Four factors were identified to be related to non-compliance with the guidelines: shock or hypotension (relative risk [RR] 5.23, 95% confidence interval [CI] 2.64-10.30; P<0.001), renal insufficiency (RR 1.80, 95% CI 1.41-2.28; P<0.001), active cancer (RR 1.35, 95% CI 1.24-1.48; P<0.001) and right ventricular dysfunction at admission (RR 1.06, 95% CI 1.01-1.11; P=0.01). The primary endpoint of all-cause death at 6 months occurred in 62 of 172 patients (36.0%) in the non-compliant group and in 131 of 1113 patients (11.8%) in the compliant group (hazard ratio 2.02, 95% CI 1.45-2.81; P<0.001). The rates of recurrent venous thromboembolism (8.7% vs 1.1%; P<0.001) and major bleeding (13.4% vs 4.9%, P=0.04) from admission to 6-month follow-up were higher in the non-compliant group. Non-compliance with guidelines was independently associated with worse outcomes, including death, recurrent venous thromboembolism and bleeding.

Sections du résumé

BACKGROUND BACKGROUND
Evidence-based clinical practice guidelines define initial management of acute pulmonary embolism (PE) according to risk stratification for early death.
AIMS OBJECTIVE
The aims of the present study were to investigate patterns of non-compliance with guidelines for the acute PE treatment, and the associated risk of adverse events.
METHODS METHODS
We performed an observational, multicentre, cohort study of acute PE. Inclusion criteria were all patients with pulmonary embolism admitted to the participating centres between January 2011 and April 2017. The measure of 100% compliance was used to allocate patients in the compliant or non-compliant groups. The primary outcome was all-cause death at 6 months. Secondary outcomes included recurrent venous thromboembolism and major bleeding.
RESULTS RESULTS
In total, 1285 patients were included. Treatment was not in compliance with the guidelines in 172 patients (13.4%). Four factors were identified to be related to non-compliance with the guidelines: shock or hypotension (relative risk [RR] 5.23, 95% confidence interval [CI] 2.64-10.30; P<0.001), renal insufficiency (RR 1.80, 95% CI 1.41-2.28; P<0.001), active cancer (RR 1.35, 95% CI 1.24-1.48; P<0.001) and right ventricular dysfunction at admission (RR 1.06, 95% CI 1.01-1.11; P=0.01). The primary endpoint of all-cause death at 6 months occurred in 62 of 172 patients (36.0%) in the non-compliant group and in 131 of 1113 patients (11.8%) in the compliant group (hazard ratio 2.02, 95% CI 1.45-2.81; P<0.001). The rates of recurrent venous thromboembolism (8.7% vs 1.1%; P<0.001) and major bleeding (13.4% vs 4.9%, P=0.04) from admission to 6-month follow-up were higher in the non-compliant group.
CONCLUSION CONCLUSIONS
Non-compliance with guidelines was independently associated with worse outcomes, including death, recurrent venous thromboembolism and bleeding.

Identifiants

pubmed: 31690519
pii: S1875-2136(19)30176-7
doi: 10.1016/j.acvd.2019.09.009
pii:
doi:

Types de publication

Journal Article Multicenter Study Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

31-39

Informations de copyright

Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Auteurs

Lisbeth Cart (L)

Department of cardiology, EA3920, university hospital Besançon, boulevard Fleming, 25030 Besançon, France.

Guillaume Serzian (G)

Department of cardiology, EA3920, university hospital Besançon, boulevard Fleming, 25030 Besançon, France.

Sébastien Humbert (S)

Department of internal medicine, hospital Besançon, boulevard Fleming, 25030 Besançon, France.

Nicolas Falvo (N)

Department of internal medicine, university hospital, 2, boulevard du Maréchal-de-Lattre-de-Tassigny, 21000 Dijon, France.

Mathilde Morel-Aleton (M)

Department of cardiology, general hospital, 2, faubourg Saint-Étienne, 25300 Pontarlier, France.

Benjamin Bonnet (B)

Department of cardiology, general hospital of Vesoul, 2, avenue René-Heymes, 70000 Vesoul, France.

Gabriel Napporn (G)

Department of cardiology, hospital center Louis-Pasteur, 73, avenue Léon-Jouhaux, 39100 Dole, France.

Elsa Kalbacher (E)

Medical oncology unit, university hospital Besançon, boulevard Fleming, 25030 Besançon, France.

Laurent Obert (L)

Orthopedic, trauma, plastic, reconstructive and hand surgery department, university hospital Besançon, boulevard Fleming, 25030 Besançon, France.

Gilles Cappelier (G)

Medical intensive care unit, EA3920, university hospital Besançon, boulevard Fleming, 25030 Besançon, France.

Yves Cottin (Y)

Department of cardiology, university hospital, 2, boulevard du Maréchal-de-Lattre-de-Tassigny, 21000 Dijon, France.

François Schiele (F)

Department of cardiology, EA3920, university hospital Besançon, boulevard Fleming, 25030 Besançon, France.

Nicolas Meneveau (N)

Department of cardiology, EA3920, university hospital Besançon, boulevard Fleming, 25030 Besançon, France.

Romain Chopard (R)

Department of cardiology, EA3920, university hospital Besançon, boulevard Fleming, 25030 Besançon, France. Electronic address: chopardromain@yahoo.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH